Mannitol for Prevention of Acute Kidney Injury After Liver Transplantation

A Randomized Controlled Trial

Moataz Maher Emara; Doaa Galal Diab; Amr Mohamed Yassen; Maha A. Abo-Zeid

BMC Anesthesiol. 2022;22(393)

Statistical Analysis

The SPSS for Windows software (version 21.0; SPSS Inc, Chicago, Ill, United States) was used to analyze available data from 80 patients (39 cases in the M group and 41 in the S group). Continuous data were tested for normalization purposes using the histogram, Q-Q plot, and the Kolmogorov-Smirnov tests.

Normally distributed data were presented as the mean (standard deviation) and compared using Student's independent t-test. Unevenly distributed data were presented as median (interquartile range) and were compared using the Mann–Whitney U test. We dealt with intraoperative serial measurement data using the area under the curve as advised by Matthews and colleagues.^[13] We then compared the groups using the Student's independent t-test.

Categorical data were depicted as numbers (percentage) and compared using the chi-squared test or Fisher's exact test, as appropriate. A two-tailed P-value of <0.05 was considered statistically significant.

1 2 3 4 5 6

Next Section

Table 1. Liver transplantation recipients' baseline characteristics and preoperative laboratory results
	Group (M) N = 39	Group S N = 41	P-Value
Age (years)	53 (43–57)	54 (45–57)	0.858
Sex (Male/Female No., %)	27/12 (69.2/30.8%)	29/12 (70.7/39.3%)	0.884
Weight (Kg)	77.62 (10.7)	78.59 (10.9)	0.69
Height (m)	1.68 (0.08)	1.68 (0.07)	0.893
Body Surface Area (m²)	1.87 (0.15)	1.88 (0.02)	0.645
MELD score	15 (12–17)	15 (11–17)	0.703
CPC	8 (7–10)	8 (6–10)	0.873
Etiology (No., %)
Viral hepatitis	19/39 (48.7%)	15/41 (36.6%)	0.445
Hepatocellular carcinoma	12/39 (30.8%)	19/41 (46.3%)
Autoimmune disease	7/39 (17.9%)	5/41 (12.2%
Cryptogenic	1/39 (2.6%)	2/41 (4.9%)
Comorbidities (No., %)
HTN	0/39	1/41 (2.5%)	0.119
DM	10/39 (25.6%)	11/41 (27.5%)
DM and HTN	0/39	5/41 (12.5%)
Cardiac (mild mitral regurgitation)	0/39	1/41 (2.5%)
Hypothyroidism	1/39 (2.6%)	0/41
S.Cr. (mg/dL)	0.7 (0.6–0.8)	0.7 (0.6–0.9)	0.221
S. AST (u/mL)	40 (30–60)	48 (39–76)	0.068
S. ALT (u/mL)	21 (21–34)	27 (21–54)	0.35
S. total bilirubin (mg/dL)	2.3 (1.6–3.3)	1.9 (1.55–3.4)	0.765
S. direct bilirubin (mg/dL)	1 (0.6–1.5)	1.1 (0.55–1.8)	0.821
S. albumin (g/dL)	2.9 (0.68)	2.8 (0.53)	0.41
INR	1.5 (0.29)	1.46 (0.29)	0.577
CRP (mg/dL)	0 (0–8)	0 (0–9)	0.808

Data are presented as mean (SD) or median (IQR), and No. (%), SD standard deviation, IQR interquartile range, M group mannitol group, S group saline group, MELD model for end-stage liver disease, CPC Child-Pugh classification, HCC hepatocellular carcinoma, HTN hypertension, DM diabetes mellitus, INR international normalized ratio, AST Aspartate Transaminase, ALT Alanine Transaminase, S serum, Cr Creatinine, CRP C-reactive protein

Table 2. Intraoperative ischemia and anhepatic phase times, operative duration, intraoperative blood product transfusion, UO, and total doses of furosemide, norepinephrine, and epinephrine
	Group (M) N = 39	Group (S) N = 41	P-Value
Cold ischemia (minutes)	28.7 (10.5)	29.8 (9.9)	0.655
Warm ischemia (minutes)	35.8 (8.6)	38.4 (9.2)	0.2
Anhepatic phase duration (minutes)	70 (15.6)	73.6 (17.3)	0.348
Operative duration (minutes)	567.6 (70.4)	576 (78.2)	0.636
RBCs (No. of patients)	24/38 (63.2%)^#	28/41 (68.3%)	0.644
Fresh frozen plasma (No. of patients)	3/38 (7.9%)^#	5/41 (12.2%)	0.713
Platelets (No. of patients)	0/38	0/41	-
RBCs (No. of units)	1 (0–3.25)	2 (0–3.5)	0.695
Plasma (No. of units)	0 (0–7)	0 (0–5)	0.549
Anhepatic phase UO (mL)	350 (200–500)	150 (50–325)	0.003*
Total UO (mL)	2100 (1340–3350)	1400 (1025–2425)	0.027*
Total intraoperative furosemide (mg)	5 (0–10)	5 (0–10)	0.528
Total intraoperative norepinephrine (mcg)	200 (77.5–275)	190 (120–270)	0.97
Total intraoperative epinephrine (mcg)	0 (0–25)	0 (0–20)	0.35

Data are presented as mean (SD), median, (IQR) or No. (%). * Indicates statistical significance (P-value <0.05), M group mannitol group, S group saline group, UO urine output, RBCs Red blood cells
#missed data of one patient

processing....

Mannitol for Prevention of Acute Kidney Injury After Liver Transplantation

A Randomized Controlled Trial

Statistical Analysis

Tables

Tables

References

Authors and Disclosures

Authors and Disclosures

Email This

Feedback